Common Contracts

CRISPR THERAPEUTICS AG 6,428,572 Common Shares (nominal value CHF 0.03 per share) Underwriting Agreement

Underwriting Agreement • July 2nd, 2020 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances) • New York

• Contract Type
  Underwriting Agreement
• Filed
  July 2nd, 2020
• Company
  CRISPR Therapeutics AG
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  New York

CRISPR Therapeutics AG, a stock corporation (Aktiengesellschaft) incorporated under the laws of Switzerland (the “Issuer”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 6,428,572 common shares, nominal value CHF 0.03 per share (“Common Shares”), of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase up to 964,285 additional Common Shares (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requir

CRISPR THERAPEUTICS AG 4,250,000 Common Shares (nominal value CHF 0.03 per share) Underwriting Agreement

Underwriting Agreement • November 22nd, 2019 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances) • New York

• Contract Type
  Underwriting Agreement
• Filed
  November 22nd, 2019
• Company
  CRISPR Therapeutics AG
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  New York

CRISPR Therapeutics AG, a stock corporation (Aktiengesellschaft) incorporated under the laws of Switzerland (the “Issuer”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 4,250,000 common shares, nominal value CHF 0.03 per share (“Common Shares”), of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase up to 637,500 additional Common Shares (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requir

CRISPR THERAPEUTICS AG 4,210,526 Common Shares (nominal value CHF 0.03 per share) Underwriting Agreement

Underwriting Agreement • September 21st, 2018 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances) • New York

• Contract Type
  Underwriting Agreement
• Filed
  September 21st, 2018
• Company
  CRISPR Therapeutics AG
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  New York

CRISPR Therapeutics AG, a stock corporation (Aktiengesellschaft) incorporated under the laws of Switzerland (the “Issuer”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 4,210,526 common shares, nominal value CHF 0.03 per share (“Common Shares”), of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer and the person named in Schedule III hereto (the “Selling Shareholder”) also propose to grant to the Underwriters an option to purchase up to the number of additional Common Shares set forth in Schedule I (the “Issuer Option Securities”) and Schedule III (the “Selling Shareholder Option Securities”), respectively (the Issuer Option Securities and the Selling Shareholder Option Securities, together, hereinafter called the “Option Securities;” the Option Securities, together with the Underwritten Secur

CRISPR THERAPEUTICS AG 5,000,000 Common Shares (nominal value CHF 0.03 per share) Underwriting Agreement

Underwriting Agreement • January 5th, 2018 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances) • New York

• Contract Type
  Underwriting Agreement
• Filed
  January 5th, 2018
• Company
  CRISPR Therapeutics AG
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  New York

CRISPR Therapeutics AG, a stock corporation (Aktiengesellschaft) incorporated under the laws of Switzerland (the “Issuer”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 5,000,000 common shares, nominal value CHF 0.03 per share (“Common Shares”), of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase up to 750,000 additional Common Shares (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requir